Skip to content
OpenCapital
Get started
Income StatementBalance SheetCash FlowSegments
Thermo Fisher Scientific logo

Thermo Fisher Scientific Cash Flow Statement

Operating, investing, and financing cash movements

Thermo Fisher Scientific generated $8.3B in operating cash flow over the trailing twelve months. After $1.5B in capital expenditures, free cash flow was $6.7B. Free cash flow increased 0.0% year-over-year. Based on the Q1 2026 filing.

Net Cash From Operating (TTM)$8.3BNet Cash From Investing (TTM)-$4.9BNet Cash From Financing (TTM)$3.0BCapital Expenditures (TTM)$1.5BDepreciation And Amortization Cf (TTM)$1.1BNet Change In Cash (TTM)-$892.0M
Latest FilingQ1 2026
Report Date2026-05-01
Market Cap$176.77B
P/E Ratio25.81
ROE13.52%

Operating

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Other non-cash income (expense)-$254M-$135M-$63M-$117M-$140M-$88M
Deferred income taxes-$202M-$279M-$322M-$127M—-$258M
Other Non-Cash Income (Expense)-$254M-$135M-$63M-$117M-$140M-$88M
Other Non-cash Income (Expense)-$254M-$135M-$63M-$117M-$140M-$88M
Other Non-cash Income (Expense)-$254M-$135M-$63M-$117M-$140M-$88M
Net cash from operating activities$3.3B$723M$1.4B$2.2B$3.5B$1.2B
Net income$1.8B$1.5B$1.6B$1.6B$2B$1.7B
Other non-cash income (expense)-$254M-$135M-$63M-$117M-$140M-$88M
Amortization of capitalized software and acquired intangible assets$438M$429M$430M$435M$436M$430M
Increase Decrease In Operating Capital Excluding Deferred Taxes—$1.4B$726M$104M—$1.1B
Other Noncash Income (Expense)-$254M-$135M-$63M-$117M-$140M-$88M
Other Non-cash Income and Expense-$254M-$135M-$63M-$117M-$140M-$88M
Other Non-Cash Adjustments-$254M-$135M-$63M-$117M-$140M-$88M
Other Non-Cash Income and Expense-$254M-$135M-$63M-$117M-$140M-$88M
Stock-based compensation$79M$75M$81M$70M$84M$83M
Change in Contract Assets and Liabilities, Net$40.5M$93.8M$93.8M$93.8M$93.8M—

Investing

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Acquisitions, net of cash acquired$0$0———$8.9B
Capital expenditures$480M$362M$294M$404M$465M$376M
Payment for (Proceeds from) Other Investing Activity-$3M$1M-$7M-$14M-$1M$55M
Proceeds from disposition of marketable securities and other investments$1.8B$2M——$1.3B$250M
Proceeds from disposals of property, plant and equipment$17M$12M$1M$4M$27M$9M
Net cash from investing activities$0-$527M-$288M-$4.1B—-$9B
Purchases of investments$1.3B$264M$47M$40M$32M$14M
Proceeds from Cross-Currency Swap Interest Settlements$49M$87M$47M$84M$50M$96M

Financing

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Proceeds from commercial paper notes$0$0———$389M
Proceeds from Commercial Paper$0$0———$389M
Proceeds from issuance of debt—$2.8B——$4.9B$5.2B
Repayments of debt$2.5B$838M$787M$0$787M$1.4B
Dividends paid$149M$149M$162M$163M$162M$162M
Proceeds from Issuance of Commercial Paper$0$0———$389M
Other, net$0$45M—-$4M$91M$39M
Payment of Deferred Purchase Consideration$0$45M—-$4M$91M$39M
Noncontrolling interest transactions and other$0$45M—-$4M$91M$39M
Net cash from financing activities-$3.7B-$102M-$991M-$632M$3.5B$1.1B
Noncontrolling Interests Activity and Other$0$45M—-$4M$91M$39M
Repurchases of common stock$1B$2B$0$963M$37M$3B

Free Cash Flow

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Free cash flow$2.8B$361M$1.1B$1.8B$3B$816M

Other

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Effect of exchange rate changes on cash-$273M$37M$311M——$78M
Net increase (decrease) in cash-$630M$132M$431M-$2.6B$7.9B-$6.6B